Skip to main content
KZIA
NASDAQ Life Sciences

Kazia Therapeutics Issues 232,956 ADSs, Raising Capital Amidst Pipeline Expansion

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$9
Mkt Cap
$99.983M
52W Low
$2.86
52W High
$17.4
52W Position info
215% above low
Off High info
48% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

KZIA has more than doubled off its 52-week low of $2.86.

Summary

Kazia Therapeutics issued 232,956 ADSs, valued at approximately $2.05 million, resulting in material dilution to fund operations and pipeline expansion, including a newly licensed epigenetic platform.


Key Events · Financing and Capital Events · KZIA

  • Share Issuance Details

    Kazia Therapeutics issued 232,956 American Depositary Shares (ADSs) at a price of $8.82 per ADS, totaling approximately $2.05 million. This issuance updates a prospectus dated December 23, 2025.

  • Material Dilution

    The issuance of these ADSs represents a material dilution to existing shareholders, providing capital for general corporate purposes and pipeline development.

  • Pipeline Expansion Incorporated

    The prospectus supplement also incorporates information from a concurrent 6-K filing regarding an exclusive worldwide license for a novel SETDB1-targeted epigenetic platform, involving an upfront payment of $1.39 million.


Analysis · KZIA · Life Sciences

This prospectus supplement details the issuance of 232,956 American Depositary Shares (ADSs), representing a significant capital raise for Kazia Therapeutics. While the filing also incorporates news of a new licensing agreement for a SETDB1-targeted epigenetic platform, that information was concurrently disclosed in a separate 6-K filing. The issuance of these ADSs, valued at approximately $2.05 million, represents a material dilution to existing shareholders, though it provides capital to support the company's ongoing operations and pipeline development, including the newly licensed platform. This issuance is part of an ongoing pattern of capital raising for the company.

At the time of this filing, KZIA was trading at $9.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $100M. The 52-week trading range was $2.86 to $17.40. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KZIA - Latest Insights

KZIA
Jul 28, 2026, 7:34 AM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $12.95
Real-time Price: $12.67 info
Change: -$0.280 (-2%) info
Market Cap: $145.007M info
KZIA
Jul 28, 2026, 7:33 AM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $12.95
Real-time Price: $12.67 info
Change: -$0.280 (-2%) info
Market Cap: $145.007M info
KZIA
Jul 28, 2026, 7:32 AM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $12.95
Real-time Price: $12.67 info
Change: -$0.280 (-2%) info
Market Cap: $145.007M info
KZIA
Jul 28, 2026, 7:31 AM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $12.95
Real-time Price: $12.67 info
Change: -$0.280 (-2%) info
Market Cap: $145.007M info
KZIA
Jun 02, 2026, 9:04 AM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $12.87
Real-time Price: $12.67 info
Change: -$0.200 (-2%) info
Market Cap: $145.007M info